SHASTA Studies

Arrowhead Pharmaceuticals is initiating two Phase 3, double-blind, placebo-controlled studies (SHASTA-3 and SHASTA-4) evaluating the efficacy and safety of plozasiran in patients with severe hypertriglyceridemia (SHTG). Plozasiran is a double-stranded, hepatocyte-targeted ribonucleic acid interference (RNAi) designed to specifically silence mRNA transcripts from the APOC3 gene using an RNAi mechanism administered subcutaneously every three months. Enrollment into SHASTA-3 and 4 will be open to adults with an established diagnosis of SHTG (≥500 mg/dL or ≥5.65 mmol/L) who are willing to remain on a stable diet and stable background lipid-lowering therapy during the 12-month, double-blind, placebo-controlled, randomized (2:1) treatment period.

If you are a clinician and would like more information about Arrowhead, plozasiran, or the SHASTA clinical trials, please contact Arrowhead Pharmaceuticals at shasta@arrowheadpharma.com.

If you are someone who struggles to control very high triglyceride levels and would like to learn more about a clinical research study enrolling now, please visit shastastudies.com.